Figure 3. Percentage of patients with relief (no or mild pain) 60 or 120 minutes after administration of sumatriptan hemisulfate nasal spray (5, 10, or 20 mg) or placebo for a recurrent headache. The number of patients using study medication to treat a recurrent headache in the 20-mg, 10-mg, and 5-mg drug groups and the placebo group was 55, 49, 51, and 24, respectively, for attack 1; 57, 54, 36, and 25, respectively, for attack 2; and 34, 30, 24, and 15 for attack 3, respectively.